TYKERB Drug Patent Profile

Which patents cover Tykerb, and what generic alternatives are available?

Tykerb is a drug marketed by Novartis and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has twenty-eight patent family members in twenty-six countries.

The generic ingredient in TYKERB is lapatinib ditosylate. There are seven drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the lapatinib ditosylate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tykerb

A generic version of TYKERB was approved as lapatinib ditosylate by NATCO PHARMA LTD on September 29^th, 2020.

Summary for TYKERB

International Patents:	28
US Patents:	1
Applicants:	1
NDAs:	1

Paragraph IV (Patent) Challenges for TYKERB

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TYKERB	Tablets	lapatinib ditosylate	250 mg	022059	1	2011-03-14

US Patents and Regulatory Information for TYKERB

TYKERB is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	TYKERB	lapatinib ditosylate	TABLET;ORAL	022059-001	Mar 13, 2007	AB	RX	Yes	Yes	8,821,927		Y	Y

International Patents for TYKERB

When does loss-of-exclusivity occur for TYKERB?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Canada

European Patent Office

Mexico

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TYKERB around the world.

Country	Patent Number	Title	Estimated Expiration
Egypt	24743	Heterocyclic compounds.
Slovenia	1294715
Poland	204958
Germany	69716916

Supplementary Protection Certificates for TYKERB

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1047694	PA2008012,C1047694	Lithuania		PRODUCT NAME: LAPATINIBUM DITOSYLATUM MONOHYDRICUM; REGISTRATION NO/DATE: EU/1/07/440/001, 2008-06-10 EU/1/07/440/002 20080610
1047694	SZ 37/2008	Austria		PRODUCT NAME: LAPATINIB ALS FREIE BASE ODER EIN SALZ ODER EIN SOLVAT DAVON
1047694	91475	Luxembourg		91475, EXPIRES: 20230610
1047694	08C0038	France		PRODUCT NAME: LAPATINIB OU UN DE SES SELS OU PRODUITS DE SOLVATATION; REGISTRATION NO/DATE: EU/1/07/440/001-002 20080610

Investment Scenario and Fundamental Analysis for Tykerb (Lapatinib)

Last updated: February 19, 2026

What is the current market positioning of Tykerb?

Tykerb (lapatinib) is an oral small-molecule tyrosine kinase inhibitor targeting HER2 and EGFR pathways. Approved by the FDA in 2007 for HER2-positive breast cancer, it remains a niche treatment with limited indications, primarily in combination with capecitabine for refractory disease. The drug's market share has declined due to the advent of more effective antibody-based therapies such as trastuzumab and pertuzumab.

Market Size and Trends

In 2022, the global HER2-positive breast cancer market was valued at approximately $4.2 billion. Tykerb captured an estimated 3-5% of this, equating to roughly $126 million to $210 million in sales. Its peak sales reached nearly $250 million in 2010 but have since decreased due to competition.

Competitive Landscape

Primary competitors include monoclonal antibodies (trastuzumab, pertuzumab) and newer TKIs like tucatinib. Innovative ADCs like trastuzumab deruxtecan are gaining approval, further challenging the small-molecule segment.

How does Tykerb's patent and regulatory status influence its investment potential?

Patent Status

The primary composition of matter patent expired in 2017, with the last data exclusivity expiring in 2019. This expiration allowed generic manufacturers to enter the market, leading to reduced pricing and sales erosion.

Regulatory Recalls and Approvals

No recent FDA safety recalls have been issued. However, approvals for additional indications have been limited. The drug retains a label for combination therapy in specific refractory HER2-positive breast cancers.

What are the key financials and pipeline developments?

Revenue and Sales

• 2022 global sales: Estimated $126–210 million.
• Decline trend consistent with patent expiry and market competition.

R&D Pipeline

No significant ongoing Phase III trials for new indications. The company may focus on label extensions or combination practices rather than novel formulations.

Licensing and Partnerships

Limited recent collaborations. Previous partnership with Novartis for broader indications has ended. Future licensing opportunities are unlikely unless new data emerges.

What are the core risks and opportunities?

Risks

• Patent expiry leading to generic entry.
• Competition from monoclonal antibodies and newer TKIs.
• Limited pipeline development.
• Market consolidation favoring combination therapies over small molecules.

Opportunities

• Potential for combination with novel agents.
• Label expansion based on emerging biomarkers.
• Strategic alliances for new formulations or delivery methods.

How should investors evaluate Tykerb as an asset?

Investors should view Tykerb primarily as a late-stage, declining product with limited growth prospects absent new indications. It may generate cash flow in the short term but faces long-term obsolescence without pipeline innovation. Acquisition or licensing could be considered if a partner plans to develop new formulations or repurpose the molecule.

Key Takeaways

• Tykerb faces patent expiration, resulting in revenue decline and generic competition.
• Its market is shrinking, with limited growth prospects due to competition from antibody therapies.
• No significant pipeline development dampens its long-term value.
• Strategic licensing could offer short-term cash flow but minimal growth potential.
• Market dynamics favor combination therapies and biologics over small molecules like Tykerb.

FAQs

1. Will Tykerb regain market share?
Unlikely, given patent expiry, generic competition, and dominance of biologic agents in HER2-positive breast cancer.

2. Are there ongoing clinical trials for Tykerb?
No significant Phase III trials reported; most recent studies focus on combination therapies or biomarkers.

3. Can Tykerb be repurposed for other indications?
Potential exists, but current data are limited; no active development programs noted.

4. How does Tykerb compare to newer TKIs?
It has a narrower target profile and less efficacy compared to newer agents like tucatinib, which have regulatory approval for brain metastases.

5. What are the licensing prospects for Tykerb?
Limited, due to patent expiry and competitive landscape; licensing for new indications or formulations is a possibility if the manufacturer pursues innovation.

---

References

[1] Grand View Research. (2023). HER2-positive breast cancer market analysis.
[2] US Food and Drug Administration. (2017). Tykerb (lapatinib) approval history.
[3] ClinicalTrials.gov. (2023). Tykerb trial registry data.
[4] IQVIA. (2022). Pharmaceutical market analytics.
[5] Strategic Pharma Reports. (2023). Small molecule vs. biologics in breast cancer therapeutics.